Literature DB >> 1914179

Six methods for direct radioiodination of mouse epidermal growth factor compared: effect of nonequivalence in binding behavior between labeled and unlabeled ligand.

C B Kienhuis1, J J Heuvel, H A Ross, L M Swinkels, J A Foekens, T J Benraad.   

Abstract

Mouse epidermal growth factor (EGF) was radioiodinated by six different direct iodination methods. The 125I-labeled EGF preparations were distinguished by analyzing the binding of the radioligand to the EGF receptor (EGFR)-containing human placental membranes. The receptor-binding affinity of EGF labeled with Chloramine T was less than the affinity of unlabeled EGF, which precluded an accurate determination of the specific radioactivity of the 125I-labeled EGF preparation by "self-displacement analysis." Scatchard analysis of competitive binding data (increasing concentrations of unlabeled EGF) obtained with commercially prepared 125I-labeled EGF (Chloramine T method), according to the specific radioactivity stated by the manufacturer, resulted in a substantial underestimation of the apparent number of receptors. Iodination of EGF with Iodogen or Iodo-beads, reagents claimed to be more gentle because of their solid state, also yielded 125I-labeled EGF preparations that were not equivalent to the native EGF in receptor binding. In contrast, equivalence in the ligand-receptor interaction between labeled and unlabeled EGF could be achieved by iodinating EGF with iodine monochloride (ICl), Protag-125, or lactoperoxidase-glucose oxidase-coupled beads (Enzymobeads). Scatchard plots of saturation and competitive binding data obtained with these 125I-labeled EGF preparations produced identical results for apparent receptor number and apparent dissociation constants. Such radioiodinated EGF preparations yield relevant binding data in competition studies of labeled and unlabeled EGF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914179

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system.

Authors:  Jennifer L Macdonald; Linda J Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-28       Impact factor: 11.205

2.  Superagonistic behaviour of epidermal growth factor/transforming growth factor-alpha chimaeras: correlation with receptor routing after ligand-induced internalization.

Authors:  A E Lenferink; R H Kramer; M J van Vugt; M Königswieser; P P Di Fiore; E J van Zoelen; M L van de Poll
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

3.  The linear C-terminal regions of epidermal growth factor (EGF) and transforming growth factor-alpha bind to different epitopes on the human EGF receptor.

Authors:  A E Lenferink; A D De Roos; M J Van Vugt; M L Van de Poll; E J Van Zoelen
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

4.  Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs.

Authors:  G R Rutteman; J A Foekens; H Portengen; J H Vos; M A Blankenstein; E Teske; C J Cornelisse; W Misdorp
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study.

Authors:  J G Klijn; M P Look; H Portengen; J Alexieva-Figusch; W L van Putten; J A Foekens
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

6.  Efficient and Site-Specific 125I-Radioiodination of Bioactive Molecules Using Oxidative Condensation Reaction.

Authors:  Sajid Mushtaq; You Ree Nam; Jung Ae Kang; Dae Seong Choi; Sang Hyun Park
Journal:  ACS Omega       Date:  2018-06-26

7.  Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.

Authors:  S C Henzen-Logmans; E M Berns; J G Klijn; M E van der Burg; J A Foekens
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.